Published in BMC Cancer on June 04, 2008
Semantic integration of data on transcriptional regulation. Bioinformatics (2010) 0.94
Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. PLoS One (2011) 0.90
Enhanced antigen uptake by dendritic cells induced by the B pentamer of the type II heat-labile enterotoxin LT-IIa requires engagement of TLR2. Vaccine (2010) 0.85
Viscum album-mediated COX-2 inhibition implicates destabilization of COX-2 mRNA. PLoS One (2015) 0.76
Immunomodulatory Effect of Gymnema sylvestre (R.Br.) Leaf Extract: An In Vitro Study in Rat Model. PLoS One (2015) 0.75
Mistletoe: from basic research to clinical outcomes in cancer and other indications. Evid Based Complement Alternat Med (2014) 0.75
Immunomodulatory effects of Ziziphora tenuior L. extract on the dendritic cells. Daru (2014) 0.75
Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model. PLoS One (2017) 0.75
Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer. BMC Complement Altern Med (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Immunobiology of dendritic cells. Annu Rev Immunol (2000) 23.65
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol (1997) 5.21
Induction of tolerance by IL-10-treated dendritic cells. J Immunol (1997) 4.65
Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med (1998) 3.58
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev (2002) 1.66
Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol (1999) 1.57
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today (1999) 1.47
A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med (1996) 1.42
Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A (1989) 1.20
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest (1993) 1.11
Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med (1996) 1.10
Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res (1999) 1.07
Isolation and properties of three lectins from mistletoe (Viscum album L.). Biochem J (1981) 1.03
Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung (2006) 1.01
A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun (1995) 0.97
T-cell response to unique and shared antigens and vaccination of cancer patients. Cancer Immun (2002) 0.94
Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem (1982) 0.94
Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol (2006) 0.91
Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett (2006) 0.90
Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biother Radiopharm (2001) 0.89
Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer. Int J Cancer (2000) 0.88
Expression of interleukin-4 in apoptotic cells: stimulation of the type-2 cytokine by different toxins in human peripheral blood mononuclear and tumor cells. Cytometry (2000) 0.88
Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. Eur J Med Res (2006) 0.87
Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res (2003) 0.84
Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung (2006) 0.82
Analysis of host versus tumor interaction in cancer patients: opposing role of transforming growth factor-beta1 and interleukin-6 in the development of in situ tumor immunity. Immunobiology (2005) 0.81
Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy. Anticancer Res (2005) 0.81
Recent studies on the anticancer activities of mistletoe (Viscum album) and its alkaloids. Oncology (1986) 0.80
Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models. Anticancer Res (2003) 0.80
Activation of dendritic cells by an aqueous mistletoe extract and mistletoe lectin-3 in vitro. Anticancer Res (2002) 0.79
Toxic proteins from European mistletoe (Viscum album L.): increase of intracellular IL-4 but decrease of IFN-gamma in apoptotic cells. Anticancer Res (2000) 0.78
Intracellular expression of IL-4 and inhibition of IFN-gamma by extracts from European mistletoe is related to induction of apoptosis. Anticancer Res (2000) 0.78
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. Leuk Lymphoma (2004) 0.77
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature (2009) 3.07
Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol (2012) 2.70
Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol (2004) 2.56
Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol (2007) 2.14
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood (2007) 1.83
High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med (2003) 1.80
Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy (2007) 1.75
A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation. Cardiovasc Res (2012) 1.63
The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med (2002) 1.62
Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol (2007) 1.57
The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther (2004) 1.56
Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood (2010) 1.53
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51
Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood (2013) 1.48
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood (2002) 1.46
Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12-26 study. AIDS (2003) 1.45
High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis (2004) 1.39
Shortage of human intravenous immunoglobulin--reasons and possible solutions. Nat Clin Pract Neurol (2007) 1.35
Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol (2008) 1.35
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A (2008) 1.34
Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol (2009) 1.30
Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood (2004) 1.30
Metrics: journal's impact factor skewed by a single paper. Nature (2010) 1.29
Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A (2005) 1.28
Compartmentalization of HIV-1 between breast milk and blood of HIV-infected mothers. Virology (2002) 1.25
PE_PGRS antigens of Mycobacterium tuberculosis induce maturation and activation of human dendritic cells. J Immunol (2010) 1.25
Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol (2011) 1.24
Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A (2004) 1.24
Natural IgM in immune equilibrium and harnessing their therapeutic potential. J Immunol (2012) 1.23
Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol (2007) 1.23
Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol (2008) 1.21
Src homology 3-interacting domain of Rv1917c of Mycobacterium tuberculosis induces selective maturation of human dendritic cells by regulating PI3K-MAPK-NF-kappaB signaling and drives Th2 immune responses. J Biol Chem (2010) 1.20
Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol (2011) 1.20
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood (2006) 1.20
Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci (2009) 1.16
Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer (2013) 1.15
Journals: Open-access boom in developing nations. Nature (2013) 1.15
Reduced immunoregulatory CD31+ T cells in patients with atherosclerotic abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol (2005) 1.15
Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS (2002) 1.14
Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol (2007) 1.14
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci (2004) 1.13
Dual role of CpG-stimulated B cells in the regulation of dendritic cells: comment on the article by Berggren et al. Arthritis Rheum (2013) 1.10
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today (2007) 1.09
Human basophils lack the capacity to drive memory CD4⁺ T cells toward the IL-22 response. J Allergy Clin Immunol (2013) 1.09
Members of protein O-mannosyltransferase family in Aspergillus fumigatus differentially affect growth, morphogenesis and viability. Mol Microbiol (2010) 1.09
Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood (2003) 1.09
Intravenous immunoglobulin-mediated regulation of Notch ligands on human dendritic cells. J Allergy Clin Immunol (2013) 1.07
Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T-cells. J Am Coll Cardiol (2007) 1.06
Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol (2002) 1.06
Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia (2002) 1.06
Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood (2008) 1.05
Interferon-α inhibition by intravenous immunoglobulin is independent of modulation of the plasmacytoid dendritic cell population in the circulation: comment on the article by Wiedeman et al. Arthritis Rheumatol (2014) 1.05
Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr (2005) 1.04
Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci (2007) 1.01
The antiinflammatory IgG. N Engl J Med (2008) 1.00
Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women. J Infect Dis (2003) 1.00
Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol (2010) 1.00
High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci U S A (2005) 0.99